Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease

Peyronie's disease (PD) is defined as the abnormal accumulation of connective tissue in the tunica albuginea of the penis, and is an ongoing physical and psychological challenge for thousands of Americans.

In vitro studies in the 1950s uncovered the potential of collagenase Clostridium histolyticum (CCH) to disrupt the collagen-containing plaques in PD, and opened the door to more in-depth clinical trials. Results indicated that with multiple dosage cycles followed by plaque modeling, penile curvature can be corrected, on average, in up to 35% of cases, with the majority of patients achieving ≥ 25% improvement in penile curvature. Most studies also indicated an improvement in patient-reported symptoms from the Peyronie's Disease Questionnaire. Adverse events from treatment with CCH included penile bruising, pain and edema, but most were mild to moderate in severity and usually resolved without intervention, suggesting that CCH is an effective and safe treatment for PD.

Drugs of today (Barcelona, Spain : 1998). 2015 Aug [Epub]

J Anaissie, M K Powers, W J Hellstrom, F A Yafi

Tulane University School of Medicine, New Orleans, Louisiana, USA. , Tulane University School of Medicine, New Orleans, Louisiana, USA. , Tulane University School of Medicine, New Orleans, Louisiana, USA. , Tulane University School of Medicine, New Orleans, Louisiana, USA.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe